ABC Mart <2670>: 2720 yen (-155 yen)
Major drop. The financial results for the first quarter were announced the previous day, with operating profit rising 9.0% YoY to 18.4 billion yen, slightly above the company's plan. The market consensus was also around 17.7 billion yen. However, based on the monthly trend at the moment, it is considered that the smooth financial results are within expectations, and there is little surprise. The full-year forecast is maintained at 58.7 billion yen, a 5.4% increase YoY. Footnote: There is a prevailing sense of fatigue due to the sluggish sales in South Korea.
Sumitomo Mining <5713>: 5232 yen (+326 yen)
Significant rise. Nonferrous metal stocks such as the company's stock have been bought due to the generally rising nonferrous metal prices in the overseas market the previous day. Copper rose 2.0%, nickel rose 1.9%, and gold rose 1.5%. In particular, the rising price of gold contributed to the rise of the company's stock, as the decline in long-term US interest rates due to the underperformance of the ISM non-manufacturing economic index and the appreciation of the euro and the depreciation of the dollar have led to the rise in gold prices.
Kawasaki Heavy Industries <7012>: 6073 yen (-378 yen)
Large drop. It has been reported that the company has solicited funds fraudulently through fictitious transactions with trading partner companies, and has borne the cost of purchasing goods and services for submarine crews of the Maritime Self-Defense Force and other personnel. The fraudulent fund-raising started at least six years ago, and the amount diverted may exceed several billion yen. Against the backdrop of expected benefits from expanding defense budgets, there is also a growing sense of uncertainty regarding future transactions with the Ministry of Defense.
Ein HD <9627>: 5574 yen (-546 yen)
Large drop. It has been announced that the company will acquire the retail business 'Franc franc' for interior goods. The acquisition price is about 50 billion yen, and the share transfer is scheduled for August 20. The operating profit for the latest fiscal period of the target company is estimated to be about 2.6 billion yen. The two companies aim to improve the wide selection of products, customer unit price and purchase number through their store collaboration. However, there is also a strong sense of uncertainty about the synergy effect due to the difference in business format and concerns about increased burden, and there seems to be a preemptive move to be cautious.
World <3612>: 2235 yen (+209 yen)
Significant rebound. The company announced its financial results for the first quarter the previous day, with operating profit rising 16.0% YoY to 6.65 billion yen, and its plan for the first half of the year, which was unchanged at 7.3 billion yen, saw a progress rate of 91.1%, up 25.0% YoY. In addition to the strong progress in EC sales, the company has also improved its sales expense rate through advances in expense control. Also, in the monthly trend for June, same-store sales increased by 10.6% YoY to make it the first time in seven months to achieve a double-digit increase.
Tim's <4891>: 267 yen (+30 yen)
A significant bullish trend has been observed since the company announced that it had signed a worldwide exclusive implementation license agreement with Hokkaido University for the intellectual property rights of candidate therapeutic agents for spinal cord injuries owned by the university. Through an option agreement signed with Hokkaido University in July 2022, the company obtained the opportunity to develop TMS-010 as a candidate therapeutic agent for spinal cord injuries. The amount of expenditure for the current fiscal year (one-time payment and annual fee for the current fiscal year) based on this agreement is included in the expected amount of research and development expenses for the fiscal year ending February 25, 2024, which was announced on April 12, 2024.
Renaissance <4889>: 373 yen (+29 yen)
A significant bullish trend has been observed since the company announced an upward revision to its earnings. The company has raised its revenue for the 2025 fiscal year from 90 million yen to 150 million yen, and its ordinary loss from a deficit of 275 million yen to a deficit of 257 million yen, and it is expected that the deficit will be reduced. The reason for the revision is that Eirion Therapeutics, Inc. in the United States, which has licensed the exclusive implementation rights for the skin disease treatment RS5441 (topical and oral medication), has started Phase I clinical trials (topical medication), and the company is scheduled to receive a milestone payment of $100,000.
Ambi DX <3300>: 1029 yen (+30 yen)
Rebound. It was announced that a proof of concept (PoC) was started with the real estate DX service "AMBITION Cloud" and Dentsu Digital's generated AI sales DX service "∞AI Chat for Sales", which is considered to be good news. The conversational AI summarizes the conversation of users searching for a room through chat, and generates a persona based on large-scale survey data that listens to consumer values by Dentsu. Based on this, the online AI creates a medical record for each user to support from introducing new properties to contracting.